Nuclear hormone receptors regulate diverse metabolic pathways and the orphan nuclear receptor LRH-1 (also known as NR5A2) regulates bile acid biosynthesis 1, 2 . Structural studies have identified phospholipids as potential LRH-1 ligands [3] [4] [5] , but their functional relevance is unclear. Here we show that an unusual phosphatidylcholine species with two saturated 12 carbon fatty acid acyl side chains (dilauroyl phosphatidylcholine (DLPC)) is an LRH-1 agonist ligand in vitro. DLPC treatment induces bile acid biosynthetic enzymes in mouse liver, increases bile acid levels, and lowers hepatic triglycerides and serum glucose. DLPC treatment also decreases hepatic steatosis and improves glucose homeostasis in two mouse models of insulin resistance. Both the antidiabetic and lipotropic effects are lost in liver-specific Lrh-1 knockouts. These findings identify an LRH-1 dependent phosphatidylcholine signalling pathway that regulates bile acid metabolism and glucose homeostasis.
Increased fat accumulation in the liver-steatosis-is tightly correlated with insulin resistance and type 2 diabetes 6 . Modestly raised bile acid levels decrease steatosis 7 . Loss of the nuclear receptor LRH-1 decreases bile acid levels 1, 2 , indicating that an LRH-1 agonist could increase them and improve fatty liver. In screens of a number of different phosphatidylcholine (PC) and other phospholipid species for effects on human LRH-1 transactivation, dilauroyl PC (DLPC; C12:0/C12:0) and diundecanoyl PC (DUPC; C11:0/C11:0) showed strong stimulation (Fig. 1a ). Comparable responses were not observed with closely related PCs differing in acyl chain length by only a single methylene group, or with any other C12:0/C12:0 phospholipid species ( Supplementary Fig. 1a-c ).
DLPC and DUPC, but not the bile acid chenodeoxycholic acid (CDCA) or the more conventional phospholipid dipalmitoyl PC (DPPC; C16:0/C16:0), also activated the synthetic LRH-1 reporter in several other cell lines, including CV-1 and HEK293T cells (data not shown), and specifically increased basal LRH-1 transactivation of the native mouse SHP promoter 8 by approximately twofold in HeLa cells ( Supplementary Fig. 2a ). DLPC and DUPC also induced a similar response with the OCT4 promoter, which was dependent on both LRH-1 cotransfection and an intact LRH-1 response element 9 ( Supplementary Fig. 2a ). DLPC and DUPC responsiveness was not altered in mutant LRH-1 derivatives previously shown to inactivate responses to LRH-1 phosphorylation 10 or sumoylation 11 , but was strongly decreased by mutations shown to block phospholipid binding 4 ( Supplementary Fig. 2d ).
Mouse and human LRH-1 showed essentially equivalent responses to DLPC and DUPC, and both DLPC and DUPC also activate the close LRH-1 relative SF-1 (also known as NR5A1; Supplementary Fig. 2 ). The LRH-1 responses were dose dependent ( Supplementary Fig. 2c ). Neither DUPC nor DLPC showed significant activation of any of a number of additional nuclear receptors outside of the NR5A subgroup ( Supplementary Fig. 2b ). In particular, DLPC and DUPC failed to activate PPARa, which was recently reported to be specifically bound and activated by 1-palmitoyl-2-oleoyl (C16:0/C18:1) PC 12 , and C16:0/ C18:1 PC failed to affect LRH-1 transactivation ( Supplementary Fig. 1a ). DLPC rapidly induced expression of the LRH-1 target CYP8B1 in the C3A derivative of HepG2 cells ( Supplementary Fig. 3a ). This response as well as CDCA repression of CYP8B1 expression and transactivation of a synthetic LRH-1 reporter plasmid was specifically compromised in cells transfected with LRH-1 short interfering RNA (siRNA; Supplementary Fig. 3b , c).
We used the mammalian two-hybrid assay and a simple GST pulldown approach to initially test the predicted function of DLPC and DUPC as LRH-1 agonist ligands. In the mammalian two-hybrid analysis, interaction of a VP16-human LRH-1 ligand-binding-domain fusion with a second fusion of the Gal4 DNA-binding domain to the nuclear receptor interaction domain of the coactivator SRC-3 (also known as NCOA3) was unaffected by vehicle, CDCA or DPPC, but was stimulated by either DUPC or DLPC ( Supplementary Fig. 4a ). In vitro, SRC-3 protein did not bind to GST alone but showed a significant basal interaction with a GST-LRH-1-ligand-binding-domain fusion protein, as expected 4 . DLPC and DUPC further increased binding of the coactivator by approximately 3 fold, but vehicle, CDCA, or any of a number of other PC species, including DPPC, had little or no effect ( Supplementary Fig. 4b ). DLPC also unexpectedly but specifically decreased binding of an SRC-2 peptide to the LRH-1 ligandbinding domain with a half-maximum inhibitory concentration (IC 50 ) of approximately 500 nM, but DPPC had no effect ( Supplementary  Fig. 4c ), and DLPC did not affect rosiglitazone binding to PPARc ( Supplementary Fig. 4d ).
As a stringent test of specific binding, the purified bacterially expressed humanLRH-1ligand-bindingdomainwasincubatedwithDLPCorDPPC at molar ratios of 1:1 or 1:5 (protein:PC), or with buffer alone, and the proteinwasthenrepurifiedtoeliminateunboundlipids.Specificallybound lipids were extracted and compared to DLPC or DPPC by electrospray ionization mass spectrometry. Phosphatidylethanolamine (PE) and phosphatidylglycerol (PG) species with 16-22 carbon acyl chain lengths occupy the ligand-binding pocket in the buffer-treated control, with the most abundant peak corresponding to 16:1/18:1 PG ( Fig. 1b ). DLPC completely replaced these Escherichia coli phospholipids, even at an added lipid to protein molar ratio of only 1:1, but DPPC showed no detectable displacement, even at a ratio of 1:5 ( Fig. 1b ). On the basis of these functional and in vitro biochemical results, as well as the extensive structural studies demonstrating phospholipid binding to NR5A receptors [3] [4] [5] 13, 14 , we conclude that DLPC and DUPC act in vitro as LRH-1 agonists. The functional results indicate that they may also act directly as agonists in vivo, although it remains unclear how they might transit the cell membrane and cytosol and enter the nucleus.
PCs are normal dietary nutrients that are efficiently absorbed in the small intestine, and we used the simple route of oral gavage to deliver cholic acid (CA), DLPC, DUPC and DPPC to C5BL/6 mice. These treatments had no apparent toxic effects and did not alter normalized liver weight ( Supplementary Fig. 5a ) or increase serum indicators of liver damage ( Supplementary Fig. 5b ). CA reduced expression of CYP7A1 and CYP8B1 and induced SHP, as expected, and DPPC was without significant effect ( Fig. 2a ). Both DLPC and DUPC significantly induced expression of CYP7A1, CYP8B1 and SR-B1, and repressed SHP ( Fig. 2a ). The substantial induction of CYP8B1, particularly by DLPC, is in accord with the opposite response in liverspecific Lrh-1 knockouts 1,2 , which otherwise show relatively limited alterations in gene expression or liver physiology. The decreased SHP expression is consistent with the induction of the bile acid biosynthetic enzymes, but was not expected based on the acute response of the isolated SHP promoter in HeLa cells ( Supplementary Fig. 2a ). Because SHP represses its own expression in the liver 8 , it is possible that an initial inductive response is followed by an autoregulatory decrease. The induction of CYP7A1 and CYP8B1 is lost in liver-specific Lrh-1 knockouts generated by infecting LRH-1 floxed (f/f) mice 2 with adenoviral Cre (Ad-Cre) expression vectors ( Supplementary Fig. 6a, b ).
These gene expression changes were associated with a modest but significant increase in the total bile acid pool and serum bile acid levels in DLPC-and DUPC-treated mice ( Fig. 2b) , consistent with the opposite effect in liver-specific Lrh-1 knockouts 1,2 . These DLPC and DUPC effects were lost in Ad-Cre-mediated liver-specific knockouts ( Supplementary Fig. 6c ). Both CA-and DUPC/DLPC-treated mice showed significantly decreased serum non-esterized fatty acids (NEFAs) ( Fig. 2b ) and hepatic triglycerides ( Fig. 2c ), which were associated with decreased serum glucose in DUPC/DLPC-treated, but not CA-treated mice (Fig. 2b ). Serum and hepatic cholesterol levels were unaffected (Fig. 2b, c) . As anticipated based on the effective clearance of phospholipid-containing gut-derived chylomicrons by the liver, neither DLPC nor DUPC altered expression of SF-1 target genes in the adrenal gland ( Supplementary Fig. 5c ).
Prompted by the lipid and glucose effects in the normal mice, we focused on DLPC, a natural product, and treated insulin-resistant leptin-receptor-deficient db/db mice for 2 weeks by oral gavage, followed by a glucose tolerance test (GTT). An insulin tolerance test (ITT) was carried out after 1 week of additional treatment. Glucose homeostasis was improved in DLPC-treated mice, as shown by the GTT and ITT ( Supplementary Fig. 7a ), as well as lower fasting serum insulin levels ( Supplementary Fig. 7e ). DLPC treatment did not affect body weight or a number of other parameters, but decreased expression of the lipogenic transcription factor SREBP-1c (also known as SREBF1) and its downstream targets, and significantly lowered hepatic triglyceride levels in the db/db mice (Supplementary Figs 7b-f and 8).
To critically test the role of hepatic LRH-1 in these antidiabetic effects, wild-type Lrh-1 f/f and liver-specific Lrh-1 2/2 mice generated using an albumin-Cre transgene ( Supplementary Fig. 9a ) were fed a high-fat diet to induce obesity and insulin resistance (diet-induced obesity (DIO)) for 15 weeks. Continuing on the diet, they were treated daily by oral gavage with vehicle or DLPC for 3 weeks, and glucose homeostasis was assessed by GTT and ITT. Loss of LRH-1 did not affect glucose homeostasis in the Lrh-1 2/2 DIO mice relative to the Lrh-1 f/f DIO mice ( Fig. 3a) . As in the db/db mice, DLPC treatment substantially improved glucose homeostasis in the Lrh-1 f/f DIO mice as indicated by GTT and ITT, and these responses were absent in the Lrh-1 2/2 DIO mice (Fig. 3a) . The DLPC treated Lrh-1 f/f DIO mice also had decreased fasting serum glucose and insulin levels, resulting in an 80% decrease in the homeostatic model assessment of insulin resistance (HOMA-IR) ( Fig. 3b ). Increased insulin sensitivity was confirmed using the hyperinsulinaemic-euglycaemic clamp, which showed both increased glucose disposal and markedly decreased hepatic glucose production in the DLPC-treated mice (Fig. 3c ). Increased overall insulin sensitivity was also confirmed by increased insulin-dependent phosphorylation of the insulin receptor, IRS2 and AKT in the DLPC-treated Lrh-1 f/f livers, but not Lrh-1 2/2 livers ( Fig. 3d and Supplementary Fig. 9c ).
Total body weight and food intake ( Supplementary Fig. 9b ), as well as weights of liver, reproductive fat pads, or brown fat did not differ between the Lrh-1 f/f and Lrh-1 2/2 DIO mice. However, the livers of DLPC-treated Lrh-1 f/f DIO mice were less pale and fatty, and decreased lipid deposition was confirmed both histologically and by direct measurement of hepatic triglyceride levels (Fig. 4a, b) . NEFA levels were also decreased by DLPC in Lrh-1 f/f , but not Lrh-1 2/2 DIO livers and serum (Fig. 4b ). Hepatic and serum bile acid levels were significantly increased by DLPC in the Lrh-1 f/f , but not the Lrh-1 2/2 DIO mice (Fig. 4b) . DLPC significantly induced both CYP7A1 and CYP8B1 expression in the Lrh-1 f/f mice, and this specific response was absent in the Lrh-1 2/2 mice ( Supplementary Fig. 10a ). The expression of additional bile-acid-related genes, including the biosynthetic CYP7B1 and CYP27A1 and the hepatic bile acid transporters BSEP (also known as ABCB11) and NTCP (also known as SLC10A1) was not significantly affected by DLPC treatment in Lrh-1 f/f DIO mice ( Supplementary Fig. 10a ). The human LRH-1 ligand-binding domain (LBD) was expressed and purified as described previously 5 and was incubated at molar ratios of 1:1 and 1:5 (human LRH-1 LBD:PC) with DLPC, DPPC or vehicle (veh) for two hours at 37 uC, and then repurified by size exclusion chromatography to remove unbound phospholipids. Bound lipids were analysed using electrospray mass injection mass spectrometry in the negativeion mode. Results with DLPC (1:1), DPPC (1:5) and vehicle are shown, along with analysis of re-extracted DLPC; DLPC (1:5) and DPPC (1:1) incubations were very similar to those shown. The re-extracted DPPC peak is at 768.5, and is not detectable in any of the DPPC incubations.
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In accord with db/db results ( Supplementary Fig. 8 ), there was little or no effect on hepatic expression of a number of glucose homeostasis and fatty acid oxidation genes ( Supplementary Fig. 10d, e ). However, DLPC markedly decreased expression of genes associated with de novo lipogenesis (Fig. 4c ), including the lipogenic transcription factor SREBP-1c and its key downstream targets ACC-2, SCD-1 and FASN in Lrh-1 f/f DIO mice (Fig. 4c ). The beneficial effects of DLPC on glucose homeostasis and fatty liver in Lrh-1 f/f mice fed a high-fat diet and infected with a control Ad-GFP vector were also lost in mice in which the Lrh-1 f/f allele was deleted by Ad-Cre expression (Supplementary Fig. 11 ). Overall, we conclude that LRH-1 is required for the antidiabetic effects of DLPC. However, it remains to be determined whether its effects are a consequence of being a direct ligand for LRH-1, and it remains possible that DLPC activates an alternative signalling cascade or induces biosynthesis of an endogenous LRH-1 ligand.
Here we have identified DLPC as a specific agonist ligand for LRH-1 in vitro. Further studies will be needed to address the intriguing questions of whether phospholipid transfer proteins 15 facilitate its transport to the large and dynamic intranuclear pool of phosphatidylcholine 16 , and whether DLPC is an endogenous LRH-1 agonist. The ligand responsiveness of LRH-1 is consistent with the identification of synthetic agonists that activate both LRH-1 and SF-1 (ref. 17) . When expressed in an adrenal cell line, SF-1 is bound by a relatively low molecular weight form of phosphatidic acid with two saturated 14 carbon acyl chains, which acts as an agonist for SF-1 but not LRH-1 (ref. 18) . Earlier results identified the sphingolipids sphingosine and lyso-sphingomyelin as potential endogenous antagonists of SF-1 transactivation 19 . DLPC does not activate other nuclear receptors, including PPARa or PPARc, which have previously been reported to be activated by more conventional longer chain phospholipid species 12, 20, 21 . In the opposite direction, LRH-1 is not activated by conventional PC species, including the C16:0/C18:1 PC reported to specifically bind and activate PPARa in the liver 12 . Phospholipids are emerging as a structurally diverse class of highly specific nuclear receptor ligands.
The beneficial effect of DLPC on steatosis is associated with significantly decreased expression of the transcription factor SREBP-1c and its downstream lipogenic targets. At least two complementary mechanisms could contribute to this decrease. As SREBP-1c autoregulates its own expression 22 , the reported functional antagonism of SREBP-1c transactivation by LRH-1 (ref. 23) could directly inhibit SREBP-1c promoter activity. As SREBP-1c expression is induced by insulin 24 , the DLPC-dependent decrease in serum insulin should also decrease SREBP-1c messenger RNA. The combination of these two mechanisms could set up a positive regulatory loop in which the initial LRH-1-dependent repression of SREBP-1c expression would decrease steatosis and increase insulin sensitivity, resulting in a decrease in serum insulin. This decrease would then reinforce the decline in SREBP-1c expression and activity, further ameliorating fatty liver and thereby continuing a beneficial cycle ( Supplementary Fig. 12 ). This essentially reverses the lipogenic vicious cycle to insulin resistance proposed previously by McGarry 25 , and supported by more recent results with SREBP-1c 26 .
These beneficial effects are probably complemented by an increase in fatty acid b-oxidation due to the decrease in acetyl-CoA carboxylase-2 (ACC-2) and its product, malonyl-CoA, which allosterically inhibits CPT-1a enzymatic activity and mitochondrial fatty acid uptake 27 . Decreasing ACC-2 activity in response to either specific antisense oligonucleotides 28 or activation of the nuclear receptor CAR 29 increases b-oxidation and has beneficial effects on both steatosis and insulin resistance. Because SCD-1 ablation also protects against hepatic steatosis by decreasing lipogenesis and increasing b-oxidation 30 , reduced SCD-1 expression may also increase b-oxidation in response to LRH-1 activation.
We conclude that the identification of DLPC as a useful tool for analysis of LRH-1 function has uncovered an unexpected, LRH-1dependent PC signalling pathway that can improve fatty acid and RESEARCH LETTER glucose homeostasis. These studies indicate that DLPC is a promising therapeutic agent for the treatment of metabolic disorders, and we have initiated a human clinical trial to explore potential beneficial effects in prediabetic patients.
METHODS SUMMARY
For transient transfection assays with HeLa, Cos-1 or C3A/HepG2 cells, candidate phospholipids dissolved in ethanol were added to cells for 24 h in medium containing 10% charcoal-treated FBS. Luciferase expression was assayed and normalized using b-galactosidase expression for transfection efficiency. Transfections were done in triplicate. For binding studies, the human LRH-1 ligand-binding domain, residues 291-541, was expressed as a maltose-binding protein fusion protein, cleaved and purified. It was incubated overnight with or without DLPC and specifically bound lipids were extracted with chloroform/methanol and analysed using electrospray mass injection mass spectrometry in the negative-ion mode to detect and identify phospholipids. LanthaScreen binding studies (Invitrogen) used full-length human LRH-1 and PPARc. For short-term animal studies, C57BL/6 mice were orally gavaged with CA, DPPC, DUPC, or DLPC delivered in a standard vehicle every 12 h for a total of five treatments. Mice were killed 4 h after the final treatment on the morning of day 3. Lrh-1 liver-specific knockout mice were generated as previously described 2 . For diabetes experiments, db/db mice were treated with vehicle or DLPC for 3 weeks. The GTT was performed 2 weeks after treatment. After an additional 1 week treatment, the ITT was performed. Eight-to-ten-week-old male control Lrh-1 f/f or Lrh-1 2/2 mice were placed on a high-fat diet (45% kcal fat) for 15 weeks. The diet was maintained and mice were treated with vehicle or DLPC by oral gavage. GTT was performed in 18 h fasted mice after 2-week treatments. One week later, ITT was performed in ad libitum fed mice. Hyperinsulinaemic clamp (insulin dose of 10 mU kg 21 
